Upstate Active Clinical Trials
Study Title:
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAF v600E or IDH1 MutationsWhat is the purpose of the study? (in Layman's terms, please describe the study)
Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAF v600E or IDH1 MutationsUpstate Institutional Review Board (IRB) Number:
1915915Study/Protocol ID:
ACNS1931Study Phase:
3Patient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWhat is involved if I participate?
- How long is the study?
27 cycles - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
surgery, blood draws, lumbar punctures, imaging
Where will the study take place?
SUNY Upstate Medical UniversityOther Information:
N/AClinicalTrials.Gov ID:
NCT0457617For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]